Abstract:IgA nephropathy is currently the most frequently investigated glomerulonephritis. The disease is defined by the presence of dominant or co-dominant deposits of IgA1 in the glomerular mesangium. Circulating immune complexes are most likely the source of the deposited IgA1. However, it is also possible that the aggregates of structurally altered IgA1 or enhanced binding to IgA receptors expressed on mesangial cells lead to deposition. The cause of the formation of immune complexes responsible for IgA nephropathy lies in the incomplete O-linked oligosaccharide side chains, which, due to the deficiency of corresponding glycosyltransferases, lack terminal galactose residues leading to the exposure of N-acetylgalactosamine. Naturally occurring antibodies of the IgG or IgA1 isotype bind to this sugar antigen. In the clinical course, we differentiate between the early stage usually characterized by hematuria, and a variable late stage characterized either by a clinical remission, by persistence of hematuria, or by increasing proteinuria and blood pressure and decreasing renal function in one third of the patients. In the early stage, it is difficult to predict the prognosis of IgA nephropathy, either on the basis of clinical presentation and morphological findings, or according to the level of galactose-deficient IgA1 in the circulation. The reliable criteria of serious prognosis emerge only in the later stages of the disease and include proteinuria, hypertension, and histologically apparent tubular atrophy and interstitial sclerosis. The dominant trend in the treatment of IgA nephropathy is the emphasis on administration of ACE inhibitors/sartans, which are introduced into the treatment at the time of microalbuminuria. If proteinuria does not decrease below 1 g/24 h, treatment with prednisone is justifiable. New findings concerning the molecular/cellular mechanism involved in the pathogenesis of IgA nephropathy suggest the possible therapeutical interference with the generation of nephritogenic immune complexes by a selective blocking of the IgA1 molecules with altered glycan structures using monovalent reagents.

[Immunoglobulin A (IgA) and its cellular receptors: Recent advances and new pathogenetical hypothesis]

Progress in Pathogenesis of Immunoglobin A Nephropathy

Recent advances in the physiopathology of IgA nephropathy

IgA glycosylation and IgA immune complexes in the pathogenesis of IgA nephropathy

Immunoglobulin A nephropathy: a pathophysiology view

Progress in molecular and genetic studies of IgA nephropathy

The pathophysiology of IgA nephropathy

An update on the pathogenesis and treatment of IgA nephropathy

Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system

Immune abnormalities in IgA nephropathy

Aberrant Glycosylation of the IgA1 Molecule in IgA Nephropathy

IgA Nephropathy: Current Treatment and New Insights

The Role of Immune Modulation in Pathogenesis of IgA Nephropathy

Gut-kidney axis in IgA nephropathy: Role on mesangial cell metabolism and inflammation

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy

IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment

IgA Nephropathy: Emerging Mechanisms of Disease

Glomerular diseases: emerging tests and therapies for IgA nephropathy

Contemporary review of IgA nephropathy

[IgA Nephropathy. Facts, uncertainties, and potential causal therapy approaches]

Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment